Literature DB >> 1635591

Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.

D P Brooks1, T A Fredrickson, J Weinstock, R R Ruffolo, R M Edwards, M Gellai.   

Abstract

The antihypertensive activity of the nonpeptide angiotensin II receptor antagonist, SK&F 108566 (E)-alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5- yl]methylene]-2-thiophene propanoic acid), was examined in rats and dogs. SK&F 108566 produced dose-dependent decreases in blood pressure in renin-dependent hypertensive rats. At 10 mg/kg intraduodenally, mean arterial blood pressure fell from between 150-160 mm Hg to approximately 124 mm Hg. A sustained infusion of SK&F 108566 at 25 micrograms/min intraduodenally normalized blood pressure during 3 days of infusion and for 18 h following cessation of the infusion. Evaluation of the systemic hemodynamic effects of SK&F 108566 in chronically instrumented renin-dependent hypertensive rats demonstrated that the antihypertensive effects of SK&F 108566 were accompanied by a significant increase in cardiac output with little change in stroke volume. In dogs made acutely hypertensive by an intravenous infusion of angiotensin I, SK&F 108566 resulted in dose-dependent decreases in blood pressure. The antihypertensive activity of SK&F 108566 at 10 mg/kg p.o. was maintained for between 13-15 h, a similar duration of action as observed with enalapril (1 mg/kg, p.o.). Administration of DuP 753 (losartan) intravenously caused a small and short-lived fall in blood pressure in the angiotensin I-infused hypertensive dog. However, the active metabolite of losartan, EXP 3174, resulted in a response of longer duration. In dogs made hypertensive by placement of an ameroid constrictor on the left renal artery, SK&F 108566 (10 mg/kg, p.o.) or enalapril (1 mg/kg, p.o.) resulted in antihypertensive responses of at least 12 h duration. The data indicate that SK&F 108566 is a long-acting antihypertensive agent in the rat and dog.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1635591     DOI: 10.1007/bf00164582

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.

Authors:  P C Wong; S D Hart; J V Duncia; P B Timmermans
Journal:  Eur J Pharmacol       Date:  1991-09-24       Impact factor: 4.432

Review 2.  Drug receptors and control of the cardiovascular system: recent advances.

Authors:  R R Ruffolo; J P Hieble; D P Brooks; G Z Feuerstein; A J Nichols
Journal:  Prog Drug Res       Date:  1991

3.  Cardioinhibitory effect of atrial peptide in conscious rats.

Authors:  D E Allen; M Gellai
Journal:  Am J Physiol       Date:  1987-03

4.  A simple procedure for direct blood pressure measurements in conscious dogs.

Authors:  W A Mann; M S Landi; E Horner; P Woodward; S Campbell; L B Kinter
Journal:  Lab Anim Sci       Date:  1987-02

5.  Role of the renin-angiotensin system in the control of vasopressin and ACTH secretion during the development of renal hypertension in dogs.

Authors:  L K Ben; J Maselli; L C Keil; I A Reid
Journal:  Hypertension       Date:  1984 Jan-Feb       Impact factor: 10.190

6.  Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).

Authors:  P C Wong; S D Hart; A M Zaspel; A T Chiu; R J Ardecky; R D Smith; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

7.  Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.

Authors:  P C Wong; W A Price; A T Chiu; D J Carini; J V Duncia; A L Johnson; R R Wexler; P B Timmermans
Journal:  Hypertension       Date:  1990-06       Impact factor: 10.190

8.  The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.

Authors:  J V Duncia; A T Chiu; D J Carini; G B Gregory; A L Johnson; W A Price; G J Wells; P C Wong; J C Calabrese; P B Timmermans
Journal:  J Med Chem       Date:  1990-05       Impact factor: 7.446

9.  Chronic arterial and venous catheterization of conscious, unrestrained rats.

Authors:  G Fejes-Tóth; A Náray-Fejes-Tóth; D Ratge; J C Frölich
Journal:  Hypertension       Date:  1984 Nov-Dec       Impact factor: 10.190

10.  Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat.

Authors:  J R Haywood; R A Shaffer; C Fastenow; G D Fink; M J Brody
Journal:  Am J Physiol       Date:  1981-08
View more
  5 in total

Review 1.  Eprosartan.

Authors:  K J McClellan; J A Balfour
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

2.  Synthesis of imidazol-2-yl amino acids by using cells from alkane-oxidizing bacteria.

Authors:  Annett Mikolasch; Elke Hammer; Frieder Schauer
Journal:  Appl Environ Microbiol       Date:  2003-03       Impact factor: 4.792

Review 3.  Eprosartan: a review of its use in the management of hypertension.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  Eprosartan: a review of its use in the management of hypertension.

Authors:  Gayle W Robins; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

Authors:  A Hilditch; A A Hunt; C J Gardner; D J Twissell; J Polley; A Travers; G M Drew; D Middlemiss; B C Ross; M J Robertson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.